Dataset Information

Selectivity profiling of SLC16A3/MCT4 inhibitor slCeMM1 using photoaffinity probe

ABSTRACT: To assess the selectivity of SLC16A3/MCT4 inhibitor slCeMM1, we derived diazirine-alkyne photoaffinity probe (slCeMM1-PAP). We next used HAP1 and MDAMB231 cell lines for MS experiment, comparing the enrichment of proteins by slCeMM1-PAP and conditions where slCeMM1-PAP was competed with slCeMM1 or it’s structurally related inactive control (S1_007). We found that among proteins enriched by slCeMM1-PAP, only SLC16A3 was competed by slCeMM1, but not S1_007, confirming the SLC16A3 engagement by slCeMM1 and suggesting overall good selectivity of slCeMM1.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Leukocyte, Epithelial Cell

DISEASE(S): Acute Leukemia,Breast Cancer

SUBMITTER: Fabian Frommelt

LAB HEAD: Dr Giulio Superti-Furga

PROVIDER: PXD040089 | Pride | 2023-10-16

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	CC_GSF_169-M1132-F1-F5-P12969-1-OTITOT-TotalPepNorm-SumInd-AR-20221213-V2.mgf	Mgf
	CC_GSF_169-M1132-F1-F5-P12969-1-OTITOT-TotalPepNorm-SumInd-AR-20221213-V2.mzML	Mzml
	CC_GSF_169-M1132-F1-F5-P12969-1-OTITOT-TotalPepNorm-SumInd-AR-20221213-V2.mzid.gz	Mzid
	CC_GSF_169-M1132-F1-F5-P12969-1-OTITOT-TotalPepNorm-SumInd-AR-20221213-V2.pdResult	Other
	CC_GSF_169-M1132-F1-F5-P12969-1-OTITOT-TotalPepNorm-SumInd-AR-20221213-V2.xlsx	Xlsx

Items per page:

1 - 5 of 16

Publications

Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors.

Dvorak Vojtech V Casiraghi Andrea A Colas Claire C Koren Anna A Tomek Tatjana T Offensperger Fabian F Rukavina Andrea A Tin Gary G Hahn Elisa E Dobner Sarah S Frommelt Fabian F Boeszoermenyi Andras A Bernada Viktoriia V Hannich J Thomas JT Ecker Gerhard F GF Winter Georg E GE Kubicek Stefan S Superti-Furga Giulio G

Cell chemical biology 20230728 8

Despite being considered druggable and attractive therapeutic targets, most of the solute carrier (SLC) membrane transporters remain pharmacologically underexploited. One of the reasons for this is a lack of reliable chemical screening assays, made difficult by functional redundancies among SLCs. In this study we leveraged synthetic lethality between the lactate transporters SLC16A1 and SLC16A3 in a screening strategy that we call paralog-dependent isogenic cell assay (PARADISO). The system invo ...[more]

PMID: 37516113

Similar Datasets

Project description:Kv1.3, a voltage-gated potassium channel, is a therapeutic target in various neuropathological conditions. In rodent models, Kv1.3 inhibitors have been shown to inhibit disease-induced neuroinflammation. However, the cellular mechanisms of disease-modification by Kv1.3 blockers and the signaling pathways regulated by Kv1.3 and are unclear. In this -study, we aim to delineate the major protective mechanisms of Kv1.3 blockade in Alzheimer’s disease (AD) pathology by investigating the brain-derived bulk and single nuclear transcriptomes (snRNAseq) and bulk proteomes, along with neurobehavioral and pathological changes in 5xFAD mice. Following 3 months of Kv1.3 blockade via either small molecule PAP-1 or ShK-223 peptide, we observed Ab plaque reduction with both drugs and improved behavior with PAP-1. snRNAseq of brain nuclei identified neuronal and glial populations with expected AD-related changes in microglia. Pseudo-bulk analyses showed that PAP-1 disproportionately impacted oligodendrocytes and microglia while ShK-223 had more pronounced effects on glutamatergic neurons. PAP-1 also increased expression of myelination genes in oligodendrocytes and synaptic genes in neurons, with distinct effects on excitatory and inhibitory neurons. Cell-cell communication analyses suggested that PAP-1 increased crosstalk between neurons and astrocytes with endothelial cells. Bulk brain transcriptomics and proteomics with PAP-1 showed increased levels of synaptic and cognitive resilience-associated proteins while decreasing glial activation and interferon (IFN) responsive genes/proteins. PAP-1 also decreased STAT1 phosphorylation in the 5xFAD brain. To gain further mechanistic insight into Kv1.3's role in interferon signaling in microglia, we confirmed physical interactions between Kv1.3 and STAT1 and STAT3 in BV2 microglia overexpressing Kv1.3. We also found that Kv1.3 blockade (PAP-1) specifically reduced type 2 IFN but not type 1 IFN-induced phosphorylation of STAT1/3, a finding with further validated in another microglial cell line as well as in primary microglia derived from wild-type or Kv1.3-knockout mice. Lastly, we identified novel proteomic changes occurring in cerebrospinal fluid that reflect disease-modification by Kv1.3 blockers. This study reveals cell type-specific effects of Kv1.3 blockers in AD pathology that correspond with reduced neuropathology and neuroinflammation, augmentation of resilience pathways and neuro-vascular coupling and translationally relevant biofluid biomarkers of therapeutic effect. We also provide novel mechanistic insights into functional coupling between Kv1.3 channels and type-2 IFN signaling pathways in microglia.